A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis

European Journal of Gynaecological Oncology

Volumn 17, Issue 3, 1996, Pages 232-233

  Balat, O ^a   Kudelka, A P ^a,b   Edwards, C L ^a   Verschraegen, C ^a   Mante, R ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hemodialysis; Ovarian cancer; Paclitaxel; Renal failure

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RENAL DIALYSIS;

EID: 0030011666     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Rowinsky E. K., Donehower R. S. C: "The clinical pharmacology of paclitaxel (Taxol)". Semin. Oncol., 1993, 10(4), 16.
2. Schilder L. E., Ergorin M. J., Zukowski E. G., Rossof A. H.: "The pharmacokinetics of Taxol in a dialysis patient". Proc. Annu. Meet. Soc. Clin. Oncol., 1994, 13, A 338.
3. Calvert A. H., Newell D. R., Gumbrell L. A., at al.: "Carboplatin dosage: Prospective evaluation of a simple formula based on renal function". J. Clin. Oncol., 1989, 17, 1748.
4. Kudelka A. P., Balat O. et al., Siddik Z. H. et al: "Carboplatin Dosimetry in Renal Failure". J. Clin. Oncol., Letter-to-the-editor, 1995, 13, 2147.
5. Caldas C., McGuire III W. P.: "Paclitaxel (Taxol) therapy in ovarian carcinoma". Semin. Oncol., 1993, 20(4), 50.
6. Rowinsky E. K., Cazeneva L. A., Donehower R. C.: "Taxol: A novel investigational antimicrotubule agent". J. Natl. Cancer Inst., 1990, 82, 1247.
7. Sonnichsen D. S., Relling M. V.: "Clinical Pharmacokinetics of paclitaxel". Clin. Pharmacokinet., 1994, 27(4), 256.